RAPT Therapeutics — Corporate Update (October 2025)
18 slides from RAPT Therapeutics's corporate update, Oct 20, 2025
Slide 1: Phase 2 Topline Results of RPT904 (JYB1904) in Chronic Spontaneous Urticaria
THE SCIENCE TO OVERCOME INFLAMMATION OCTOBER 20, 2025 Phase 2 Topline Results of RPT904 (JYB1904) in Chronic Spontaneous Urticaria
Slide 2: Disclaimer
Disclaimer Statements in this Presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding the development of RPT904, including the expected timing of clinical trials and the availability of
Slide 3: Summary of RPT904 Phase 2 Results in CSU
Summary of RPT904 Phase 2 Results in CSU RPT904 at both Q8W and Q12W dosing showed comparable efficacy and safety to omalizumab at Q4W dosing Both RPT904 arms showed numerically superior efficacy to omalizumab arm on UAS7 and UAS7=0 (complete response) across all timepoints* Sustained efficacy out t
Slide 4: IgE is Key Driver of Allergic Reactions
SENSITIZATION PHASE EFFECTOR PHASE IgE is Key Driver of Allergic Reactions Allergen is first introduced – Immune response is initiated Captures allergen, presents it to T cells Promotes B cell development Produces IgE antibodies Th2 Cell B Cell/ Plasma Cell APC ALLERGIC REACTION Food Allergy Chronic
Slide 5: Omalizumab is Highly Effective in CSU and is Standard of Care
Omalizumab is Highly Effective in Chronic Spontaneous Urticaria and is Standard of Care Results not from head-to-head trials; no direct comparisons can be made. Omalizumab 300 mg Q4W REMIBRUTINIB 25 mg BID DUPILUMAB 300 mg Q2W -11.3 -5.0 -6.3 -7.9 -6.8 -13.4 -12.6 REMIX-1 REMIX-2 RILZABRUTINIB 400 m
Slide 6: RPT904 is a Next Generation anti-IgE Antibody Bio-Better
RPT904 is a Next Generation anti-IgE Antibody Bio-Better with Several Potential Advantages over Omalizumab * RAPT primary research CSU demand study of n=50 allergists Longer half-life Higher potency Improved drug-like properties Same epitope Strong IP RPT904 OMA RPT904 Potential Advantages Over Omal
Slide 7: CSU Phase 2 Trial Design (Jeyou)
CSU Phase 2 Trial Design (Jeyou) Primary Endpoint: Change from baseline in UAS7 at Week 8, 12, 16 Secondary: UAS7=0, ISS7, HSS7, AAS7, DLQI at Week 8, 12, 16 N=135 (1:1:1), 45 per arm China sites 16-Week Follow Up RPT904 300 mg Q12W (N=45) RPT904 300 mg Q8W (N=45) Omalizumab 300 mg Q4W (N=45) Random
Slide 8: Subject Disposition
Subject Disposition 187 Screened Omalizumab Q4W N=45 Completed Week 16 43 (95.6%) N=137 Randomized RPT904 Q8W N=46 3 (6.5%) discontinued 1 Withdrawal of Consent 1 Non-compliance 1 Personal Reason 2 (4.4%) discontinued 0 Withdrawal of Consent 1 Non-compliance 1 Insufficient Efficacy Completed Week 16
Slide 9: Key Demographics and Baseline Characteristics
Key Demographics and Baseline Characteristics * Discontinuation of omalizumab for non-efficacy reasons only. Minimum 4-month washout period (prior to Screening) Characteristics RPT904 Q8W (N = 46) RPT904 Q12W (N = 46) Omalizumab (N = 45) Age (years) – Mean (SD) 41.5 (13.3) 40.2 (13.6) 38.0 (12.8) Fe
Slide 10: Primary Endpoint: Change from Baseline in UAS7
Primary Endpoint: Change from Baseline in UAS7 * Estimated based on the MMRM model, using the change from baseline in UAS7 values as the dependent variable, the baseline UAS7 score as the covariate, and randomization stratification factors (prior use of omalizumab or other biologic agents used for C
Slide 11: Secondary Endpoint (Itch and Hive Severity Score)
Secondary Endpoint (Itch and Hive Severity Score) * LS mean was estimated by the MMRM model: the model had baseline score as a covariate, with randomization-stratified factors (prior use of omalizumab or other biologics used in CSU), group, visit, and the interaction between group and visit as fixed
Slide 12: Secondary Endpoint: Proportion of Subjects with UAS7=0 (Complete Response)
Secondary Endpoint: Proportion of Subjects with UAS7=0 (“Complete Response”) * Proportion of UAS7=0 subjects using LOCF-filled outcomes with CMH chi-square test for stratification (prior use of omalizumab or other biologics used in CSU). % Subjects with UAS7=0 Weeks
Slide 13: Safety Summary
Safety Summary † AESI: Grade 5 allergic reactions according to the WAO Grading System for Systemic Allergic Reaction n (%) Patients RPT904 Q8W (N = 46) RPT904 Q12W (N = 46) Omalizumab Q4W (N = 45) Any TEAE 31 (67.4) 33 (71.7) 29 (64.4) Treatment-related 13 (28.3) 12 (26.1) 10 (22.2) Treatment-relate
Slide 14: Comments from Dr. Ana Maria Giménez-Arnau, MD PhD
Comments from Dr. Ana Maria Giménez-Arnau, MD PhD Dr. Gimenez-Arnau is a consultant to RAPT. Professor at the Hospital del Mar Research Institute (IMIM) and Associate Professor of Dermatology at Universitat Pompeu Fabra in Barcelona Specialist in immunoallergic skin diseases More than 300 internatio
Slide 15: Conclusions
Results from this randomized double-blind phase 2 study show that extended half life and pharmacodynamic effects of RPT904 translate to durable clinical benefit A single 300 mg dose of RPT904 showed numerically superior efficacy to four 300 mg doses of omalizumab at week 16* Data support promise of
Slide 16: RPT904 Food Allergy Phase 2b Trial Design
RPT904 Food Allergy Phase 2b Trial Design Primary Endpoint: Prespecified threshold by oral food challenge N=100 (2:2:1 Q12W, Q8W regimens and placebo) US/Canada/Australia clinical sites FPI in 2H 2025, ~18 months from FPI to topline data Treatment Extension and Placebo Crossover RPT904 Q12W regimen
Slide 17: RPT904 Clinical Development Overview and Anticipated Milestones
1H 2025 2H 2025 1H 2026 2H 2026 1H 2027 2H 2027 FA Phase 2b Start N=100 Topline Data CSU Phase 2 or 3 Start Phase 2 CSU Data N=135 RPT904 Clinical Development Overview and Anticipated Milestones Phase 2 Asthma Data N=60 Phase 3 CSU Start Phase 3 Asthma Start PK/PD Data
Slide 18: Thank You
Thank You Please visit www.rapt.com